Pancreatic Cancer Therapeutics Market to Reach $2.92 Billion by 2021

Market survey and study claim global revenues for the Pancreatic Cancer Therapeutics Market are forecast to rise at a moderate CAGR of 7.6% from $1.746 Billion in 2014 to $2.92 Billion in 2021.

Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC.

Pancreatic cancer is caused by the unrestrained growth of cells in the pancreas. This abnormal, uncontrolled growth of cells leads to the formation of lumps of tissue, commonly referred to as tumors. The presence of tumors hinders the normal functioning of pancreas.

Complete research on Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 available at:
http://www.marketintelreports.com/report/gbihc377mr/pancreatic-cancer-therapeutics-in-major-developed-markets-to-2021–strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-market-landscape

Future Forecast: 5 new drugs and G17DT pipeline therapies are expected to drive the revenue of the PC Therapeutics Market by the end of 2021, to a certain extent.

Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, HyperAcute Pancreas, G17DT and clivatuzumab tetraxetan. But anyway, the high costs of these drugs in the initial few years will make it an average segment but is hoped to shoot in sales during the much future years. The pipeline therapies G17DT is expected to have the strongest performance, with revenues of $141 Million by 2021, confirms Pancreatic Cancer Therapeutics Market research.

Market Trends: Resection is the present best possible option for treating and increasing the lifespan of the victim.

Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unresectable stages of PC.

According to research, the ways have shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline is drugs inhibiting signal transduction. The dynamics of the remaining 49% of the pipeline is explained in detail in the report. Also how this reflects the need for novel targeted methods and therapies is also provided in the same.

The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

Check research sample here:
http://www.marketintelreports.com/pdfdownload.php?id=gbihc377mr

Market Driving Factors: Growing age and old age; the largest market drivers.

Increasing aging population across the globe, higher growth records of diabetes and rising obesity issues have been projected to be the top few reasons driving the Pancreatic Cancer Therapeutics Market during the forecast period, 2014-2021. While on the other hand, the aggressive nature of this cancer has posed an immense threat to the overall healthcare department globally, has been acting as a market barrier.

Regions Analyzed: The U.S. confirmed as the largest contributor of the global Pancreatic Cancer Therapeutics Market.

On studying and understanding various regions from around the world like the US, Canada, UK, France, Germany, Italy, Spain and Japan, experts have concluded that the U.S. is the biggest geography in terms of most number of pancreatic cancer patients. Being recorded that there are around 30,000 victims each year, there is a strict need for a better and more polished Pancreatic Cancer Therapeutics Market. This disease offers a horrendous lesser-than-five-years lifetime to the victim and has been least lucky in being met with successful methods to either cure or extend the disease. This has proven a challenge to the entire oncology domain.

Prominent Market Competitors:

• Merck Serono
• Threshold Pharma
• GSK Enters
• OncoMed Pharmaceuticals
• OncoMed Pharma
• Celgene Corporation
• Baxter International
• Onconova Therapeutics
• Janssen Biotech
• Pharmacyclics 

These are few of the many companies analyzed and mentioned in pancreatic cancer therapeutics market report.

Order a copy of Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 report at:
http://www.marketintelreports.com/purchase.php?id=gbihc377mr

On a related note, another research on  Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) – Identifying and Commercializing First-in-Class Innovation available at:
http://www.marketintelreports.com/report/gbihc378mr/frontier-pharma-chronic-obstructive-pulmonary-disease-copd–identifying-and-commercializing-firstinclass-innovation

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/02/1455019048.jpeg

“Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 – Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape”

Media Contact
Company Name: MarketIntelReports
Contact Person: Mayur S.
Email: sales@marketintelreports.com
Phone: 1-302-684-6088
Address:2711 Centerville Road, Suite 400
City: Wilmington
State: Delaware
Country: United States
Website: www.marketintelreports.com

Source: ABNewswire

ReleaseID: 51995